Education
About Us
Working with TipRanks
Follow Us
Molecular Partners (MOLN)
NASDAQ:MOLN
MOLN Stock Chart & Stats
$4.39
-$0.03(-0.55%)
At close: 4:00 PM EST
$4.39
-$0.03(-0.55%)
Day’s Range― - ―
52-Week Range$3.36 - $5.91
Previous CloseN/A
Volume8.30K
Average Volume (3M)2.31K
Market Cap
$180.55M
Enterprise Value$1.32M
Total Cash (Recent Filing)$104.52M
Total Debt (Recent Filing)$1.53M
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Mar 12, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.69
Shares Outstanding40,374,640
10 Day Avg. Volume2,377
30 Day Avg. Volume2,311
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)1.04
Price to Sales (P/S)29.53
P/FCF Ratio-2.45
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.03
Enterprise Value/Ebitda-0.02
Forecast
1Y Price Target
$10.00Price Target Upside127.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressMOLN reiterated plans for initiating a company-sponsored Phase 1 by the end of 2025 with longer-term plans for registration opportunities in SCLC and other neuroendocrine carcinomas.
Drug EfficacyMP0712 has achieved ~60% injected dose on the tumor due to radio-DARPin half-life extension via albumin binding and rapid DLL3 internalization & recycling.
Financial StabilityAs of 9/30/2025, MOLN had CHF 105M cash and equivalents, which will support its runway until 2028.
Bears Say
Treatment ChallengesThe benefit of obinutuzumab pretreatment remained limited, indicating challenges in enhancing treatment efficacy.
Treatment EffectivenessThe presence of anti-drug antibodies coincided with reduced serum MP0533 exposure levels and the loss of T cell activation in 53% of patients, limiting the treatment's effectiveness.
Tumor TargetingIn spite of DLL3's 'very low' cell surface density, MP0712 has achieved ~60% injected dose on the tumor.
Molecular Partners News
MOLN FAQ
What was Molecular Partners’s price range in the past 12 months?
Molecular Partners lowest stock price was $3.36 and its highest was $5.91 in the past 12 months.
What is Molecular Partners’s market cap?
Molecular Partners’s market cap is $180.55M.
When is Molecular Partners’s upcoming earnings report date?
Molecular Partners’s upcoming earnings report date is Mar 12, 2026 which is in 81 days.
How were Molecular Partners’s earnings last quarter?
Molecular Partners released its earnings results on Aug 25, 2025. The company reported -$0.687 earnings per share for the quarter, missing the consensus estimate of -$0.474 by -$0.213.
Is Molecular Partners overvalued?
According to Wall Street analysts Molecular Partners’s price is currently Undervalued.
Does Molecular Partners pay dividends?
Molecular Partners does not currently pay dividends.
What is Molecular Partners’s EPS estimate?
Molecular Partners’s EPS estimate is -0.39.
How many shares outstanding does Molecular Partners have?
Molecular Partners has 40,374,640 shares outstanding.
What happened to Molecular Partners’s price movement after its last earnings report?
Molecular Partners reported an EPS of -$0.687 in its last earnings report, missing expectations of -$0.474. Following the earnings report the stock price went down -7.82%.
Which hedge fund is a major shareholder of Molecular Partners?
Currently, no hedge funds are holding shares in MOLN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Molecular Partners
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
MOLN Stock 12 Month Forecast
Average Price Target
$10.00
▲(127.79% Upside)
Technical Analysis
Compugen
―
Oncolytics Biotech
―
Oncolytics Biotech
―
Nkarta
―
C4 Therapeutics
―
Shattuck Labs
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
8.86% Other Institutional Investors
91.14% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---